Search

• GSK’s Nucala® (mepolizumab) receives approval from US FDA

  Media

  First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-nucala-mepolizumab-receives-approval-from-us-fda/

  First published: 04 November 2015

• GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD

  Media

  GSK and Theravance, Inc. today announced the start of a global phase III study, known as IMPACT.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-initiation-of-phase-iii-programme-with-fixed-dose-triple-combination-treatment-ffumecvi-in-patients-with-copd/

  First published: 16 July 2014

• GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma

  Media

  GSK updated results for Tafinlar® from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAFV600E metastatic melanoma.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-overall-survival-results-from-phase-iii-break-3-study-of-tafinlar-dabrafenib-in-patients-with-braf-v600e-mutant-metastatic-melanoma/

  First published: 29 September 2014

• New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age

  Media

  New data published in The Lancet from a Phase III clinical trial with Fluarix Tetra which prevented influenza in children 6 to 35 months

  https://www.gsk.com/en-gb/media/press-releases/new-clinical-data-demonstrate-high-vaccine-efficacy-of-fluarix-tetra-influenza-vaccine-in-children-6-35-months-of-age/

  First published: 06 March 2018

• Results announcement for the fourth quarter 2016

  Media

  View full Q4 2016 Results (PDF)

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2016/

  First published: 08 February 2017

• China National Medical Products Administration accepts regulatory submission for Nucala (mepolizumab) in severe eosinophilic asthma

  Media

  The China National Medical Products Administration (NMPA) has accepted for review a new drug application for Nucala (mepolizumab)

  https://www.gsk.com/en-gb/media/press-releases/china-national-medical-products-administration-accepts-regulatory-submission-for-nucala-mepolizumab-in-severe-eosinophilic-asthma/

  First published: 14 March 2023

• Japan’s Ministry of Health, Labour and Welfare approves Shingrix for the prevention of shingles in at-risk adults aged 18 and over

  Media

  Approval expands the number of people who can be protected against shingles.

  https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-approves-shingrix-for-the-prevention-of-shingles-in-at-risk-adults-aged-18-and-over/

  First published: 26 June 2023

• GSK announces first approval of Shingrix in Canada

  Media

  The only shingles vaccine to achieve ≥90% efficacy in adults aged 50 and over

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-approval-of-shingrix-in-canada/

  First published: 13 October 2017

• GSK’s Synflorix™ receives CHMP positive opinion for major label extension

  Media

  GSK announced that the CHMP of EMA has issued a positive opinion for the expansion of the SynflorixTM European label

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-synflorix-receives-chmp-positive-opinion-for-major-label-extension/

  First published: 27 July 2015

• Four initiatives from across Africa win share of global US$1 million Healthcare Innovation Award

  Media

  Organisations from South Africa, Zambia, Kenya and Uganda and Save the Children for innovations proven to help reduce deaths in under-fives

  https://www.gsk.com/en-gb/media/press-releases/four-initiatives-from-across-africa-win-share-of-global-us-1-million-healthcare-innovation-award/

  First published: 29 January 2015